When it comes to clinical delivery of such assays, the ability to work with FFPE tissue is critically important.
Toronto, Canada (PRWEB) August 22, 2013
The field of personalised medicine is developing rapidly and companion diagnostic approvals are becoming more and more common. To date, however, the vast majority of tests are relatively low complexity DNA or protein based assays.
More complex gene signature based tests are beginning to enter the pipeline with many of our clients currently using these tests for trial enrichment strategies as early as Phase I.
When it comes to clinical delivery of such assays, the ability to work with FFPE tissue is critically important. This is an area of significant experience and expertise for experts working at Almac.
Some of the key components covered in this webinar include:
- Platforms, platform selection and migration
- Optimising tests for FFPE tissue
- Clinical delivery for trial enrichment
- Development routes for companion diagnostics
A Q&A with the audience will follow the main presentation.
For more information about this event or to register, visit http://xtks.in/FFPE-for-biomarker-strategies-Description .
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com/ContactUs.ashx .
Karen Lim (416) 977-6555 ext 227